252 Pre-treatment IL-15 serum levels correlate with the incidence and severity of neurological events following the administration of anti-CD19 CAR-T cellsMadison Davis, Davide Bedognetti, Justin A. Budka et al.|Regular and Young Investigator Award Abstracts|2024Cited by 1
Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphomaSoumya Poddar, Sattva S. Neelapu, Madison Davis et al.|Journal of Clinical Investigation|2025Cited by 1
Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene CiloleucelSoumya Poddar, Sattva S. Neelapu, Jiali Yan et al.|Blood|2024Cited by 0
In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 TranscriptSoumya Poddar, Mike Mattie, Gabriela Balderrama-Gutierrez et al.|Blood|2024Cited by 0